Guilford Gliadel Survival Data Could Address FDA “Non-Approvable” Letter

Guilford Pharmaceuticals may submit Gliadel Wafer patient survival data to help address concerns outlined in FDA's March 19 "non-approvable" letter for a newly diagnosed malignant glioma indication